$FibroGen(FGEN.US)$ NEWS FIBROGEN ANNOUNCES CLINICAL DATA FROM DOSE ESCALATION PHASE 1B STUDY OF FG-3246 (FOR46) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WILL BE PRESENTED AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Dr. Adib's appointment, with his vast oncology drug development experience, is viewed as a crucial step to speed up FibroGen's oncology pipeline and deliver innovative cancer treatments. His leadership is anticipated to aid the company's ongoing and future clinical development activities.
Analysts are more negative on FibroGen post-earnings, cutting revenue estimates and predicting higher losses. Despite projected revenue growth, FibroGen's expected growth is slower than the industry. The consensus price target dropped significantly, showing analysts' lack of confidence in the latest results and a lower future valuation estimate for FibroGen.
Investors expect limited future growth, contributing to the company's low P/S ratio. The underwhelming revenue outlook makes a strong share price rise unlikely.
Insiders selling shares at low prices may signal expected stock weakness. Lack of insider purchases and low insider ownership cast doubt on the company's future. Five warning signs also unsettle analysts.
FibroGen股票討論區
NEWS
FIBROGEN ANNOUNCES CLINICAL DATA FROM DOSE ESCALATION PHASE 1B STUDY OF FG-3246 (FOR46) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WILL BE PRESENTED AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
🎯 Ph 3 readouts in Q2 2024...
$CG Oncology(CGON.US)$ Phase 3
$美國聯合醫療(UTHR.US)$ Phase 3
$美國聯合醫療(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...
here are 6 cancer readouts to watch this quarter:
$ImmunityBio(IBRX.US)$ : Anktiva ▻ PDUFA ▻ Bladder CA
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib ▻ PDUFA ▻ Glioma
$GlycoMimetics(GLYC.US)$ : Uproleselan ▻ Ph3 ▻ AML
$FibroGen(FGEN.US)$ : Pamrevlumab ▻ Ph3 ▻ Pancreatic CA
$Viracta Therapeutics(VIRX.US)$ : Nana-val ▻ Ph3 ▻ Lymphoma
Biotech Stock Catalyst Watchlist
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$和黃醫藥(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...
Biotech Stock Catalyst Watchlist
$輝瑞(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood醫藥(IRWD.US)$ Phase 3
$阿里拉姆制藥(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$$Novocure(NVCR.US)$ Phase 3
$羅氏(ADR)(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$阿卡迪亞(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...
暫無評論